Table 3.
Methodological quality of the NRCCTs.
| Author (year) | A | B | C | D | E | F | G | H | I | J | K | L | Total score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gu, 2018 | 2 | 0 | 2 | 2 | 0 | 2 | 0 | 0 | 2 | 2 | 2 | 2 | 16 |
| Gu, 2014 | 2 | 0 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 16 |
| Hou，2014 | 2 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 2 | 2 | 2 | 2 | 14 |
| Walicka, 2018 | 2 | 0 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 16 |
| Wang, 2013 | 2 | 0 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 16 |
| Ye, 2017 | 2 | 0 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 16 |
| Yu,2011 | 2 | 0 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 16 |
| Zhao, 2012 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 18 |
A: a clearly stated aim; B: inclusion of consecutive patients; C: prospective collection of data; D: endpoints appropriate to the aim of the study; E: unbiased assessment of the study endpoint; F: follow-up period appropriate to the aim of the study; G: loss to follow-up less than 5%; H: prospective calculation of the study size; I: an adequate control group; J: contemporary group; K: baseline equivalence of group; L: adequate statistical analyses.(0 = not reported, 1 = inadequately reported, and 2 = adequately reported).